Dicot AB (publ)

Dicot AB (publ)
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Dicot is developing the drug candidate LIB-01 (formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market. Dicot is listed on Spotlight Stock Market and has approximately 1,600 shareholders. For more information, please visit www.dicot.se

Contacts

Göran Beijer
goran.beijer@dicot.se

Dicot invited to present at ESSM for the third time

Fri, Jan 05, 2024 09:53 CET

Press release: Uppsala, Sweden, January 5, 2024. The pharmaceutical company Dicot's preclinical research results have been selected to be presented at the European Society for Sexual Medicine's conference in February. It is the third year in a row that Dicot will present at Europe's largest event in the field of sexual medicine.The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine whose annual conference brings together prominent researchers and doctors from all over the world. The ESSM Scientific Council has selected Dicot's

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Links

Dicot invited to present at ESSM for the third time

Subscribe